Polymyxin Otilonium Bromide Composition for Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multi-drug-resistant (MDR) Gram-negative bacteria, particularly those resistant to colistin, are limited by toxicity, side effects, and the emergence of resistant strains, with existing adjuvants lacking in vivo efficacy data and mechanistic understanding.
Innovation Solution
A drug composition combining an effective amount of a polymyxin, such as colistin, with otilonium bromide, a FDA-approved drug, and a pharmaceutically-acceptable carrier, which synergistically enhances the antimicrobial activity of polymyxins against resistant Gram-negative bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If colistin is used to treat MDR Gram-negative bacteria, then antimicrobial efficacy is improved, but toxicity and side effects increase
Solution Approach 1:
Otilonium bromide serves as an intermediary substance that modifies the bacterial cell membrane to enhance colistin's binding affinity and antimicrobial activity. The adjuvant acts as a mediator that facilitates colistin's action against resistant bacteria while allowing reduction of colistin dosage, thereby reducing toxicity.
Solution Approach 2:
The invention changes the chemical and biological parameters of the bacterial cell membrane through otilonium bromide treatment, making the membrane more susceptible to colistin. This parameter change enables effective treatment at lower colistin concentrations, reducing the harmful effects associated with high-dose colistin therapy.
2Reliability
If colistin concentration is increased to overcome resistance, then antimicrobial activity is improved, but toxicity increases
Solution Approach 1:
Otilonium bromide acts as an intermediary that restores colistin's effectiveness against resistant bacteria by modifying membrane properties, enabling treatment at lower colistin concentrations and thereby reducing toxicity while maintaining antimicrobial activity.
Solution Approach 2:
Otilonium bromide is administered to preliminarily modify the bacterial cell membrane before colistin treatment, making the bacteria susceptible to colistin at lower concentrations. This preliminary action avoids the need for high colistin doses and their associated toxicity.
3Reliability
If existing colistin adjuvants are used, then antimicrobial potency is improved, but in vivo efficacy and mechanistic understanding are lacking
Solution Approach 1:
Otilonium bromide, an FDA-approved drug with known safety profile and established pharmacological properties, serves as the adjuvant. Its well-characterized mechanisms of action provide inherent mechanistic understanding, and its approved status implies available in vivo efficacy data, eliminating the information gap present with experimental adjuvants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of otilonium bromide and polymyxins effectively re-sensitizes resistant bacteria to colistin, reducing the required drug concentration and associated toxicity, while also enhancing the bactericidal activity against both susceptible and resistant strains.
Implementation Method 1
otilonium bromide may re-sensitize Gram-negative bacteria to a polymyxin; especially colistin, colistimethate sodium, colistin sulfate, polymyxin B, and a combination thereof
Data Source
AI summary
A drug composition contains an effective amount of a drug active containing a polymyxin, an effective amount of otilonium bromide, and a pharmaceutically-acceptable carrier. A method for treating or protecting against a Gram-negative infection containing the step of administering a drug composition, a disinfecting composition similar to the drug composition, and an adjuvant for a drug active also may contain otilonium bromide.